Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares react to a mix of upbeat analyst actions and a flurry of class-action lawsuit filings. Investors are weighing positive earnings and price-target revisions against potential legal overhangs.

• Positive Sentiment: Shares jumped more than 5% after a MarketBeat piece highlighted the surge, prompting fresh buy-side interest in SRPT stock. Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.7% - Should You Buy?
• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for SRPT from $0.67 to $0.71 and lifted its full-year outlook, signaling stronger projected profitability. Sarepta Therapeutics Zacks Research Upgrade
• Positive Sentiment: JPMorgan Chase & Co. assigned a new $28.00 price target on SRPT shares, reflecting increased confidence in Sarepta’s mid-term valuation. Sarepta Therapeutics (NASDAQ:SRPT) Given New $28.00 Price Target at JPMorgan Chase & Co.
• Negative Sentiment: Pomerantz LLP filed a securities-fraud class action against SRPT, urging investors who sustained losses to submit claims before upcoming deadlines. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines
• Negative Sentiment: Bernstein Liebhard LLP issued a shareholder alert, notifying SRPT investors of a securities-fraud suit and a fast-approaching filing deadline. SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
• Negative Sentiment: The Schall Law Firm invited SRPT investors to lead a federal securities-fraud class action, covering share purchases from June 2023 through June 2025. SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The DJS Law Group reminded SRPT shareholders of their right to serve as lead plaintiff in a class action over alleged federal securities-law violations. SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline
• Negative Sentiment: The Gross Law Firm issued notice of a class action against SRPT, encouraging shareholders to inquire about lead-plaintiff opportunities. The Gross Law Firm Notifies Sarepta Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
• Negative Sentiment: Robbins Geller Rudman & Dowd LLP announced SRPT investors with significant losses can seek lead plaintiff status in an ongoing securities-fraud case. SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
• Negative Sentiment: GuruFocus highlighted the same Robbins Geller opportunity for SRPT shareholders, underscoring the growing legal scrutiny. SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit